Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / erythrocyte micronucleus
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From October 7, 2019 to Decenber 13, 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 019
- Report date:
- 2019
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 474 (Mammalian Erythrocyte Micronucleus Test)
- GLP compliance:
- yes
- Type of assay:
- mammalian erythrocyte micronucleus test
Test material
- Reference substance name:
- Reaction products of cuprate(4-), [C-(aminosulfonyl)-C-[[[2-[[4-chloro-6-[(2,5-disulfophenyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]amino]sulfonyl]-29H,31H-phthalocyanine-C,C-disulfonato(6-)-N29,N30,N31,N32]-, tetrasodium and lithium chloride
- Molecular formula:
- C43H24ClCuN15O16S6.xLi.yNa, (x + y) = 4; 0 < (x,y) < 4 with 1341.9 < MW < 1374 g/mol (UVCB substance), and traces of NaCl and NaSO4
- IUPAC Name:
- Reaction products of cuprate(4-), [C-(aminosulfonyl)-C-[[[2-[[4-chloro-6-[(2,5-disulfophenyl)amino]-1,3,5-triazin-2-yl]amino]ethyl]amino]sulfonyl]-29H,31H-phthalocyanine-C,C-disulfonato(6-)-N29,N30,N31,N32]-, tetrasodium and lithium chloride
- Test material form:
- solid: particulate/powder
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- ICR
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- - Animal species: 25 of 6 weeks male ICR mice.
- Source: BioLASCO Taiwan Co., Ltd
- Temperature: 22±3℃
- Relative humidity: 55±15%
- Light cycle: 12 hours light and 12 hours dark
- Animal feeding situation: 5 mice per cage. Frequency of ventilation: 10~15 times/hour.
- Drinking water: Reverse osmosis water provided with water bottle.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- Test article was prepared with reverse osmosis water to 200.0000, 100.0000 and 50.0000 mg/mL, respectively.
- Details on exposure:
- The dosing volume of negative control and test article was 10 mL/kg BW by intraperitoneal injections.
- Duration of treatment / exposure:
- 72 hours
- Frequency of treatment:
- During study period, the clinical observation of the mice was conducted every day. The body weights of the mice were determined before getting started with administration (Day 1) and 72 hours after the administration (Day 4).
- Post exposure period:
- 48 and 72 hours after the test article administration, 5 µL of blood were collected from submandibular. The blood specimens were placed on slides that pre-dyed with acridine orange (1 mg/mL) and covered with coverslips. The blood were uniformly spread to a one layer blood cell thickness, and placed under room temperature for 3 hours protecting from light. Subsequently, fluorescence microscope was employed to observe the number of reticulocytes and micronucleus.
Doses / concentrationsopen allclose all
- Dose / conc.:
- 50 mg/kg bw/day (nominal)
- Remarks:
- Positive control group
- Dose / conc.:
- 500 mg/kg bw/day (nominal)
- Remarks:
- Low dose group
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Remarks:
- Medium dose group
- Dose / conc.:
- 2 000 mg/kg bw/day (nominal)
- Remarks:
- High dose group
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Positive control(s):
- Article name: Cyclophosphamide monohydrate (CPP)
Major ingredients: CPP, Form: Powder
Storage condition: Refrigeration (5±3℃)
Examinations
- Evaluation criteria:
- 1. Clinical observations were conducted during the study period and animal deaths should be documented.
2. The ratio of reticulocytes: Fluorescence microscope was employed to calculate the number of reticulocytes, stained with orange-red color, per 2,000 erythrocytes.
3. The micronucleus incidence: Fluorescence microscope was employed to calculate the number of micronucleated reticulocytes, micronuclei was stained with yellow-green color, per 4,000 reticulocytes.
4. The body weight of test and control groups were analyzed by using One-Way ANOVA of Duncan’s multiple range test in SPSS software. The ratio of reticulocyte and the micronucleus incidence of test and control groups were analyzed by using median and Mann-Whitney U test in SOSS software. A significant difference was defined as p< 0.05.
5. Positive criteria: The micronucleus incidence had statistic difference compared with negative control group, and showed dose-response relation.
1. Clinical observations were conducted during the study period and animal deaths should be documented.
2. The ratio of reticulocytes: Fluorescence microscope was employed to calculate the number of reticulocytes, stained with orange-red color, per 2,000 erythrocytes.
3. The micronucleus incidence: Fluorescence microscope was employed to calculate the number of micronucleated reticulocytes, micronuclei was stained with yellow-green color, per 4,000 reticulocytes.
4. The body weight of test and control groups were analyzed by using One-Way ANOVA of Duncan’s multiple range test in SPSS software. The ratio of reticulocyte and the micronucleus incidence of test and control groups were analyzed by using median and Mann-Whitney U test in SOSS software. A significant difference was defined as p< 0.05.
5. Positive criteria: The micronucleus incidence had statistic difference compared with negative control group, and showed dose-response relation. - Statistics:
- Quality control: The ratio of reticulocyte and micronucleus in the negative control group at 48 hour and 72 hour should be in the range of laboratory historical data. The ratio of reticulocytes in the positive control group was significantly lower than negative control group and the micronucleus incidence was significantly higher than negative control group, then considered as effective data.
Results and discussion
Test results
- Sex:
- male
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- 1. During study duration, results of body weight in all test groups showed no significantly different with negative control group (p>0.05) (Table 1). It indicated that test article had no influence on animal body weight.
2. The clinical observation results showed that testing mice of all groups were survival till the end of the study and no abnormal clinical sign were observed (Table 2).
3. The results of reticulocytes observation in 48 hours showed that the reticulocytes ratio median of negative control group was 56.0‰. The positive control group was 20.5‰ and significantly lower than negative control group (p<0.05). The low dose and medium dose group were 53.5‰ and 54.0‰ in reticulocytes ratio median, respectively. There were no significant difference compared with negative control group (p>0.05). The high dose group was 45.5‰ in reticulocytes ratio median and significantly lower than negative control group (p<0.05) (Table 3).
4. The results of micronucleus observation in 48 hours showed that the micronucleus incidence median of negative control group was 0.3‰. The positive control group was 10.5‰ and significantly higher than negative control group (p<0.05). The low dose, medium dose, and high dose group were 0.5‰, 0.5‰ and 0.5‰ in micronucleus incidence median respectively. There were no significant difference compared with negative control group (p>0.05) (Table 3).
5. The results of reticulocytes observation in 72 hours showed that the reticulocytes ratio median of negative control group was 56.0‰. The positive control group was 19.0‰ and significantly lower than negative control group (p<0.05). The low dose and medium dose group were 52.5‰ and 52.5‰ in reticulocytes ratio median, respectively. There were significantly lower than negative control group (p<0.05). The high dose group was 51.0‰ in reticulocytes ratio median. Tjere was no significant difference compared with negative control group (p<0.05) (Table 3).
6. The results of micronucleus observation in 72 hours showed that the micronucleus incidence median of negative control group was 0.5‰. The positive control group was 10.8‰ and significantly higher than negative control group (p<0.05). The low dose, medium dose, and high dose group were 0.3‰, 0.3‰ and 0.3‰ in micronucleus incidence median, respectively. There were no significant difference compared with negative control group (p>0.05) (Table 3).
Any other information on results incl. tables
Table 1. The body weight of testing mice
Group | Dose (mg/kg BW) | Body weight (g)a | |
Day 1 | Day 4 | ||
Negative control group | - | 28.2±0.8 | 29.6±0.8 |
Positive control group | 50 | 28.5±0.8 | 30.0±0.9 |
Test group | |||
Low dose group | 500 | 28.6±1.4 | 30.1±1.0 |
Medium dose group | 1000 | 29.3±1.0 | 30.9±1.7 |
High dose group | 2000 | 28.5±1.2 | 30.0±1.4 |
aAll data were shown as mean±SD, n=5.
Table 2. Clinical observation of testing mice
Group | Dose (mg/kg BW) | Daily Clinical Observation | |||
Day 1 | Day 2 | Day 3 | Day 4 | ||
Negative control group | - | N | N | N | N |
Positive control group | 50 | N | N | N | N |
Test group | |||||
Low dose group | 500 | N | N | N | N |
Medium dose group | 1000 | N | N | N | N |
High dose group | 2000 | N | N | N | N |
aN: Normal.
Table 3. Reticulocytes ratio and micronucleus incidence in peripheral blood of all groups mice
Group | Dose (mg/kg BW) | Reticulocytes ratio RETs/2000 RBCs (‰)a |
Micronucleus incidence Mn-RETs/4000 RBCs (‰)b |
||
Medianc (Q1~Q3) |
p valued | Median (Q1~Q3) |
p valued | ||
48 hours | |||||
Negative control group | - | 56.0(51.8~58.8) | - | 0.3 (0.2~0.7) | - |
Positive control group | 50 | 20.5(14.5~21.8) | 0.008* | 10.5(10.2~11.1) | 0.008* |
Test group | |||||
Low dose group | 500 | 53.5(49.8~57.3) | 0.413 | 0.5(0.0~0.9) | 0.833 |
Medium dose group | 1000 | 54.0(51.5~56.8) | 0.548 | 0.5(0.2~08) | 0.810 |
High dose group | 2000 | 45.5(44.5~48.3) | 0.008* | 0.5(0.0~0.9) | 0.833 |
72 hours | |||||
Negative control group | - | 56.0(54.3~59.5) | - | 0.5(0.3~0.8) | - |
Positive control group | 50 | 19.0(16.8~21.3) | 0.008* | 10.8(10.4~13.4) | 0.008* |
Test group | |||||
Low dose group | 500 | 52.5(50.8~53.8) | 0.016* | 0.3(0.2~0.7) | 0.468 |
Medium dose group | 1000 | 52.5(50.8~53.5) | 0.016* | 0.3(0.2~0.7) | 0.468 |
High dose group | 2000 | 51.0(50.3~59.5) | 0.381 | 0.3(0.2~0.7) | 0.468 |
aReticulocytes ratio: Reticulocytes (RETs)/2000 red blood cells (RBCs), n=5
bMicronucleus incidence: Reticulocytes with micronucleus (Mn-RETs) / 4000 reticulocytes (RETs), n=5.
c Q1: first quartile; Q3: third quartile.
d Analysis by Mann-Whitney U test.
*Significantly different compared with negative control group, p<0.05
Applicant's summary and conclusion
- Conclusions:
- The reticulocytes ratio of high dose group at 48 hours and low and medium dose groups at 72 hours were significantly lower than negative control group, but the average value were in the range of laboratory historical data. Therefore, it did not affect the determination of genotoxicity in this test. The micronucleus incidence of low, medium and high dose groups were no significantly different with negative control group. In conclusion, the test article CJ303 showed negative reaction for rodent peripheral blood micronucleus test under the conditions designed for this study, no mutagenic potential.
- Executive summary:
This study was conducted according to the OECD474:2016 to evaluate the mutagenicity of CJ303 by rodent peripheral blood micronucleus test. Testing system was male ICR mice. The study included negative control group, positive control group and three test groups including 500, 1000 and 2000 mg/kg BW. Five testing animal were used per group. In this study, blood specimens of all group mice were collected and prepared for blood slide after 48 and 72 hours of test article or control article administration. Using fluorescence microscope observed the reticulocytes and number of micronucleus. Results showed that the reticulocytes ratio of high dose group at 48 hours and low and medium dose groups at 72 hours were significantly lower than negative control group, but the average value were in the range of laboratory historical data. Therefore, it did not affect the determination of genotoxicity in this test. The micronucleus incidence of low, medium and high dose groups were no statistical different compared with negative control group. The reticulocytes ratio of positive group was significantly lower than negative control group and the micronucleus incidence of positive control group was significantly higher than negative control group. In conclusion, CJ303 showed negative reaction for rodent peripheral blood micronucleus test under the conditions designed for this study, no mutagenic potential.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.